MAGENTUM 1 HeartMate 3 LVAS: A Single Center Prospective Controlled Study (MAGENTUM 1)
Status:
Active, not recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to obtain single-center safety and feasibility data on patients
managed with reduced anti-coagulation, and the incidence of thrombotic and bleeding adverse
events associated with the HeartMate 3 LVAS therapy.